MARKET

DYN

DYN

Dyne Therapeutics, Inc.
NASDAQ
11.83
+0.09
+0.77%
After Hours: 11.75 -0.08 -0.68% 18:49 05/16 EDT
OPEN
11.77
PREV CLOSE
11.74
HIGH
12.09
LOW
11.56
VOLUME
2.19M
TURNOVER
--
52 WEEK HIGH
47.45
52 WEEK LOW
6.36
MARKET CAP
1.34B
P/E (TTM)
-3.2920
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at DYN last week (0505-0509)?
Weekly Report · 5d ago
Dyne Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 05/09 12:54
Dyne Therapeutics Price Target Cut to $38.00/Share From $46.00 by HC Wainwright & Co.
Dow Jones · 05/09 12:54
HC Wainwright & Co. Maintains Buy on Dyne Therapeutics, Lowers Price Target to $38
Benzinga · 05/09 12:43
Analysts Are Bullish on These Healthcare Stocks: Dyne Therapeutics (DYN), Argenx Se (ARGX)
TipRanks · 05/09 12:30
Optimistic Buy Rating for Dyne Therapeutics Driven by Promising Clinical Progress and Regulatory Advancements
TipRanks · 05/09 11:26
Dyne Therapeutics price target lowered to $38 from $46 at H.C. Wainwright
TipRanks · 05/09 11:21
RBC Capital Keeps Their Buy Rating on Dyne Therapeutics (DYN)
TipRanks · 05/09 11:09
More
About DYN
Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. Its product candidate, DYNE-101, is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, DYNE-251, is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to exon 51 skipping. Its other product candidates are DYNE-302 and DYNE-401. DYNE-302 addresses the genetic basis of FSHD.

Webull offers Dyne Therapeutics Inc stock information, including NASDAQ: DYN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DYN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DYN stock methods without spending real money on the virtual paper trading platform.